Selank vs Semax: Research Comparison

Origins & Development

Both Selank and Semax were developed at Russian research institutions in the Soviet/post-Soviet era, a period that produced several unique neuropeptide research compounds not developed in Western pharmaceutical pipelines.

Selank was developed at the Institute of Molecular Genetics (IMG) of the Russian Academy of Sciences. It is a heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) — a stabilized analogue of the endogenous immunopeptide tuftsin (Thr-Lys-Pro-Arg), extended with a Pro-Gly-Pro C-terminal tripeptide to improve stability and CNS penetration.

Semax was developed at the Institute of Molecular Genetics and also at Moscow State University. It is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) based on the ACTH(4-10) fragment, specifically the 4-7 sequence responsible for cognitive effects, stabilized with a C-terminal Pro-Gly-Pro extension.

Both are approved in Russia as pharmaceutical products (Selank for anxiety disorders, Semax as a nootropic/neuroprotectant). Neither has received FDA or EMA approval. All Rainbow Peptide products are For Research Use Only.

Selank: Mechanism & Research Profile

Selank's primary studied mechanisms include:

• GABA-A receptor modulation: Research suggests Selank may modulate GABA-A receptor activity, though the precise binding site is not fully characterized. This is consistent with its studied anxiolytic effects in rodent behavioral models.
• Cytokine modulation: Selank has been shown to decrease IL-6 and IL-1β expression in stimulated macrophage cultures and in rodent acute stress models, suggesting immunomodulatory activity.
• Tryptophan metabolism: Some studies suggest Selank influences serotonin synthesis through effects on tryptophan hydroxylase activity — a potential mechanism for mood and anxiety effects.
• Enkephalin metabolism: Selank has been shown to inhibit enkephalin-degrading enzymes, prolonging endogenous opioid peptide activity.

In rodent behavioral models (elevated plus maze, open field test, Vogel conflict test), Selank consistently reduces anxiety-like behavior without the sedation associated with benzodiazepines — a key finding that distinguishes its pharmacological profile.

Semax: Mechanism & Research Profile

Semax's primary studied mechanisms include:

• BDNF upregulation: Semax is one of the most potent peptide BDNF inducers studied. Multiple rodent studies document 130–160% increases in hippocampal BDNF expression following intranasal Semax administration — a finding that drives much of the nootropic and neuroprotective research interest.
• NGF upregulation: Nerve growth factor expression is also upregulated in frontal cortex tissue in published rodent studies.
• Dopamine & serotonin modulation: Semax increases dopamine and serotonin turnover in several brain regions in rodent models, consistent with stimulant and mood effects reported in limited clinical observations.
• Neuroprotection in ischemia models: Semax has been studied in rodent stroke models, showing reduction in infarct volume and improved neurological outcomes — effects attributed to its BDNF upregulation and anti-inflammatory activity.

BDNF Modulation: The Key Mechanistic Difference

Brain-derived neurotrophic factor (BDNF) is the most important single mechanistic difference between these two peptides for neurological research:

• Semax is a potent BDNF inducer. Published data documents substantial (100%+) increases in hippocampal BDNF within 1–2 hours of intranasal administration in rodents. BDNF drives synaptic plasticity, LTP (long-term potentiation), neurogenesis, and neuroprotection.
• Selank shows more modest and indirect BDNF effects. Some studies report mild BDNF upregulation, but this is not considered a primary mechanism. Selank's primary CNS targets appear to be GABA and cytokine systems rather than neurotrophic pathways.

For researchers studying neuroplasticity, learning and memory models, or neuroprotection endpoints, Semax is the more relevant compound. For anxiety, stress, and immunomodulatory CNS models, Selank is more appropriate.

Anxiolytic Research: Selank's Signature

Selank's anxiolytic profile in rodent models is one of the most reproducible findings in the peptide nootropic research literature:

• Elevated plus maze: Selank increases time in open arms (reduced anxiety) at doses of 25–300 µg/kg in mice and rats without sedation (locomotor activity unchanged)
• Light-dark box: Increased exploration of light compartment (anxiolytic endpoint) comparable in magnitude to diazepam in some studies, without diazepam's sedation or motor impairment
• Stress-induced immune changes: Selank attenuates the IL-6 elevation normally observed in acute restraint stress models — linking its behavioral and immunomodulatory effects

Semax does not have the same anxiolytic profile. Some studies report mild anxiolytic effects, but this is secondary to its main nootropic and neuroprotective research applications.

Head-to-Head Comparison Table